Citius Oncology, Inc. (CTOR)
NASDAQ: CTOR · Real-Time Price · USD
2.000
-0.250 (-11.11%)
At close: Aug 16, 2024, 4:00 PM
2.080
+0.080 (4.00%)
After-hours: Aug 16, 2024, 7:59 PM EDT
Company Description
Citius Oncology, Inc. develops a oncology therapies.
The company was formerly known as Citius Acquisition Corp. and changed its name to Citius Oncology, Inc. in May 2023.
Citius Oncology, Inc. was incorporated in 2021 and is headquartered in United States. The company operates as a subsidiary of Citius Pharmaceuticals, Inc.
Citius Oncology, Inc.
| Country | United States |
| Founded | 2021 |
Contact Details
No contact details available.
Stock Details
| Ticker Symbol | CTOR |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001851484 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Xiaofeng Yuan | Chief Executive Officer and Chairman |
| Dahe Zhang | Chief Financial Officer and Executive Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 16, 2024 | 8-K | Current Report |
| Aug 16, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Aug 15, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Aug 13, 2024 | 25-NSE | Filing |
| Aug 9, 2024 | 10-Q | Quarterly Report |
| Aug 5, 2024 | 8-K | Current Report |
| Jul 19, 2024 | 425 | Filing |
| Jul 19, 2024 | 8-K | Current Report |
| Jul 12, 2024 | EFFECT | Notice of Effectiveness |
| Jul 12, 2024 | 424B3 | Prospectus |